跳至主要内容
临床试验/NCT06604273
NCT06604273招募中2 期

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年4月3日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
10
试验地点
2
主要终点
Candidate fibrotic cellular pathways

研究概览

简要总结

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults with confirmed diagnosis of UC - Group 1 criterion: ≥18 years of age regardless of gender
  • Group 2 criterion: ≥30 years of age for males and ≥40 years of age for females
  • Active disease confirmed by endoscopy (endoscopic Mayo score ≥ 2)
  • Indication to start treatment with filgotinib
  • AND one of the following criteria:
  • Active disease confirmed by intestinal ultrasound (BWT > 3 mm in at least one bowel segment and at least one other pathological IUS parameter) or
  • Increased CRP (>5 mg/L) and/or fecal calprotectin levels (>250 mg/kg)

排除标准

  • Pregnancy
  • Unable to provide informed consent
  • Colorectal carcinoma or high-grade dysplasia

结局指标

主要结局

Candidate fibrotic cellular pathways

时间窗: From enrollment to end of study participation at 24 weeks

Identification of candidate fibrotic cellular pathways using single cell pathway analysis and mucosal biopsies from UC patients before and at week 24 weeks after treatment initiation with filgotinib.

次要结局

  • 68Ga-FAPi-PET/CT imaging feasibility(From enrollment to end of study participation at 24 weeks)
  • Correspondance 68Ga-FAPi uptake and STAT expression(From enrollment to end of study participation at 24 weeks)
  • Correspondance 68Ga-FAPi uptake and clinical and endoscopic parameters(From enrollment to end of study participation at 24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dalia Lartey

Drs

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (2)

Loading locations...

相似试验